CARsgen Signs Partnership Agreement with Shanghai Cancer Institute

CARsgen, a clinical stage Shanghai company developing cancer immunotherapies, signed a five-year partnership agreement with the Shanghai Cancer Institute to develop CARsgen's Chimeric Antigen Receptors T (CAR-T) immunotherapeutics. In addition, the partners will identify and develop novel CAR-T candidates as well as next-generation CAR-T technologies. CARsgen will own rights to the drugs. In March 2015, CARsgen initiated a Phase I clinical study of its glypican 3 (GPC3) chimeric antigen receptor T-cell (CAR-T) therapy in patients with refractory hepatocellular carcinoma (HCC), the most common type of liver cancer. The treatment has been demonstrated to be safe in all treated patients. More details.... Share this with colleagues: // //